2 completed, 1 not yet recruiting, 1 terminated, 1 unknown. 2 Phase 4, 1 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 1, Unknown 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Type 2 Diabetic Nephropathy: new trials by email Literature Review of Type 2 Diabetic Nephropathy trials Research Report on Type 2 Diabetic Nephropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients DWP16001 Placebo, DWP16001 0.3mg - Type 2 Diabetic Nephropathy | Phase 3 | Not yet recruiting | Daewoong Pharmaceutical Co. LTD. | 348 | 2024-09-23 | 2024-09-20 |
| Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy Dulaglutide Injection - Type 2 Diabetic Nephropathy | Not applicable | Completed | The Affiliated Hospital of Xuzhou Medical University | 300 | 2021-10-30 | 2023-12-27 |
| Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan Alfacalcidol, Irbesartan - Type 2 Diabetic Nephropathy | Phase 4 | Completed | The Third Xiangya Hospital of Central South University | 60 | 2016-07-28 | 2019-10-10 |
| A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy PF-03882845, Spironolactone, placebo - Type 2 Diabetic Nephropathy | Phase 1 | Terminated | Pfizer | 6 | 2012-01-01 | 2013-10-29 |
| Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Compound α-Ketoacid Tablet - Type 2 Diabetic Nephropathy | Phase 4 | Unknown | Shanghai Jiao Tong University School of Medicine | 60 | 2011-02-01 | 2011-09-08 |
Diabetes Complications (2) · Diabetes Mellitus (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Urogenital Diseases (2) · Urologic Diseases (2)
(3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo(g)indazole-7-carboxylic acid (1) · Enavogliflozin (1) · Irbesartan (1) · Spironolactone (1) · alfacalcidol (1) · dulaglutide (1) · ketosteril (1)
Daewoong Pharmaceutical Co. LTD. (1) · Pfizer (1) · Shanghai Jiao Tong University School of Medicine (1) · The Affiliated Hospital of Xuzhou Medical University (1) · The Third Xiangya Hospital of Central South University (1)
China (3) · South Korea (1) · United States (1)
Hao Zhang, Doctor (1) · Renhao Wang, Ph.D (1) · Weijie Yuan, Professor (1)